Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TYMP | P19971 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | CCR10 | P46092 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28639392 | 0.91 | LMNA (0.52) | LMNATHRBCYP2C19KMT2ATYMP | |
| SCHEMBL21327770 | 0.91 | LMNA (0.52) | LMNATHRBCYP2C19KMT2ATYMP | |
| SCHEMBL16284421 | 0.86 | LMNA (0.48) | LMNATHRBCYP2C19KMT2ATYMP | |
| SCHEMBL14822352 | 0.86 | LMNA (0.48) | LMNATHRBCYP2C19KMT2ATYMP | |
| SCHEMBL26657822 | 0.86 | CYP2C19 (0.48) | LMNATHRBCYP2C19KMT2ATYMP | |
| SCHEMBL14822584 | 0.86 | LMNA (0.48) | LMNATHRBCYP2C19KMT2ATYMP | |
| SCHEMBL9441389 | 0.79 | LMNA (0.50) | LMNATHRBCYP2C19KMT2ATYMP | |
| SCHEMBL18823119 | 0.78 | LMNA (0.49) | LMNATHRBCYP2C19KMT2ATYMP | |
| SCHEMBL8530813 | 0.76 | LMNA (0.59) | LMNATHRBCYP2C19KMT2ATYMP | |
| SCHEMBL15597325 | 0.76 | TYMP (0.56) | LMNATHRBCYP2C19KMT2ATYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3536686-B1 | METHOD FOR PRODUCING A RADIOPHARMACEUTICAL COMPOSITION | NIHON MEDIPHYSICS CO LTD (JP) | 2021-11-24 | — | — | EP | disclosed |
| EP-3536686-B1 | METHOD FOR PRODUCING A RADIOPHARMACEUTICAL COMPOSITION | NIHON MEDIPHYSICS CO LTD (JP) | 2021-11-24 | — | — | EP | disclosed |
| US-10703726-B2 | Method for producing radiopharmaceutical composition | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20190276411-A1 | Method for Producing Radiopharmaceutical Composition | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3536686-A1 | METHOD FOR PRODUCING A RADIOPHARMACEUTICAL COMPOSITION | NIHON MEDI-PHYSICS CO., LTD (JP) | 2019-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703726-B2 | Method for producing radiopharmaceutical composition | NAA15, TMEM14C, FLNA | LMNA 2138/4885THRB 438/4885CYP2C19 226/4885 |
| US-20190276411-A1 | Method for Producing Radiopharmaceutical Composition | NAA15, TMEM14C, FLNA | LMNA 2138/4885THRB 438/4885CYP2C19 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.